Edwards Lifescience Sees Q4 EPS $0.60-$0.66, Sales $1.45B-$1.53B vs $1.54B Est.
Portfolio Pulse from Benzinga Newsdesk
Edwards Lifesciences has projected its Q4 earnings per share (EPS) to be between $0.60 and $0.66, with sales ranging from $1.45 billion to $1.53 billion. This is lower than the estimated sales of $1.54 billion.
October 25, 2023 | 8:27 pm
News sentiment analysis
Sort by:
Ascending
NEGATIVE IMPACT
Edwards Lifesciences' lower than expected sales forecast for Q4 could potentially impact its stock price.
Edwards Lifesciences' projected sales for Q4 are lower than the estimated $1.54 billion. This could lead to a negative market reaction, potentially causing a decrease in the company's stock price in the short term.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100